# OnCo record checkmate-214 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/checkmate-214/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "checkmate-214", "NCT02231749" ;
  schema:name "CheckMate 214"@en ;
  schema:description "CheckMate 214 is the trial that brought dual immunotherapy to kidney cancer, with a survival advantage still visible eight years later and a fifth of patients in long-term remission."@en ;
  schema:url <https://onco.cc/trials/checkmate-214/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02231749> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2014-10-16" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/clear-cell-rcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/sunitinib/> ;
  onco:terms <https://onco.cc/terms/imdc-risk/> ;
  onco:people <https://onco.cc/people/robert-motzer/>, <https://onco.cc/people/laurence-albiges/> .